Twelfth annual Vanderbilt Research Retreat set for Oct. 4Sep. 24, 2013, 5:09 PM
The Vanderbilt University community is invited to attend the 12th annual Research Retreat—a showcase of cutting-edge biomedical science by Vanderbilt faculty members and trainees—on Friday, Oct. 4, in Langford Auditorium.
At 9:45 a.m., Kathleen Neuzil, director of the global Vaccine Access and Delivery Program for the global health care organization PATH, will give the keynote address, “Success in Global Health Research: Persistence, Partnership and Passion.”
Neuzil earned her M.D. from Johns Hopkins, her master of public health from Vanderbilt, completed residencies in internal medicine and infectious diseases here and is a former Vanderbilt faculty member.
Prior to joining PATH, she held full-time faculty positions at the University of Washington, where she remains on the clinical faculty. For nearly 40 years, Seattle-based PATH has pioneered development and delivery of health care solutions worldwide.
The Oct. 4 event is organized by the Office of Clinical and Translational Scientist Development and presented by the Elliott Newman Society, the Translational Bridge, and the Master of Science in Clinical Investigation and Master of Public Health programs.
Katherine Hartmann, associate dean for clinical and translational scientist development, will open the retreat at 8 a.m.
Gordon Bernard, associate vice chancellor for clinical and translational research and director of the Vanderbilt Institute for Clinical and Translational Research, will follow with remarks before the five plenary presentations begin at 8:15 a.m.
The faculty speakers and their topics are:
- Meira Epplein, assistant professor of medicine, “Helicobacter pylori subtypes and risk of gastric cancer”;
- Kevin Ess, assistant professor of neurology, pediatrics and cell and developmental biology, “Easter Island: Big heads and big brains”;
- Christine Lovly, assistant professor of medicine and cancer biology, “Developing novel therapeutic strategies for ALK-fusion positive lung cancer”;
- James Luther, assistant professor of medicine and pharmacology, “The role of aldosterone in diabetes progression”; and
- Matthew Resnick, instructor in urologic surgery, “Temporal variation in reporting disease-specific function among prostate cancer patients: Has the ‘Bob Dole Effect’ reset the baseline?”
At 11 a.m., 12 Vanderbilt scholars who hold either newly awarded R01s, K or equivalent awards, or are MSCI or MPH trainees, will discuss their research in concurrent sessions.
Contact: Donna Marie, (615) 322-4785